摘要
目的:探讨帕利哌酮缓释片和利培酮治疗首发精神分裂症患者的有效性和安全性。方法:54例首发精神分裂症患者随机分成帕利哌酮缓释片组和利培酮组,在治疗前及治疗后第2、4、8周分别进行阳性及阴性症状量表(positive and negative symtoms scales,PANSS)和治疗中出现的不良反应量表(treatment emergent symtoms scale,TESS)评定。结果:帕利哌酮缓释片组有效率74.07%,利培酮组有效率70.37%,两组疗效差异无显著性,但帕利哌酮缓释片组不良反应较利培酮少且轻微。结论:帕利哌酮缓释片与利培酮对精神分裂症的疗效相当,不良反应轻微。
Objective： To explore the efficacy and safety of paliperidone and risperidone in the treatment of patients with naive senile schizophrenia. Methods：54 naive senile schizophrenic patients were randomly assigned to paliperidone or risperidone treatment for 8 weeks. All patients were evaluated with positive and negative symtoms scales （PANSS）and treatment emergent symptom scale （TESS） before treatment and at 2, 4, 8 week. Results： The response rate of paliperidone was 74.07% similar to the rate of olanzap ineT0.37% ,paliperidone had light side effect. Conclusions： Paliperidone and risperidone were both effective in treatment of schizo phrenia. Paliperidone were with light side effect.
出处
《中国民康医学》
2012年第19期2360-2361,共2页
Medical Journal of Chinese People’s Health
